RVNC News and Press, Revance Therapeutics Inc. From 09/08/22

Biotechnology company Revance Therapeutics ( NASDAQ: RVNC ) said that the U.S. Food and Drug Administration has approved its DAXXIFY product for injection for the temporary improvement of moderate to severe frown lines in adults. The peptide-formulated neuromodulator ...

The shares of Revance Therapeutics ( NASDAQ: RVNC ), a biotech focused on neuromodulators, added ~14% in the pre-market trading Thursday after the company announced the FDA approval of Daxxify injection for the temporary improvement of moderate to severe frown lines. The d...

Approved label includes full 36-week efficacy data from Phase 3 SAKURA clinical program, positioning DAXXIFY™ as the first and only long-acting neuromodulator that demonstrates a median duration of six months and up to nine months for some patients 1- 6* ‡ ...

Summary Form 483 observation in press release did not contain important detail. Burkholderia cepacia complex contamination found in manufacturing process. Inspection may not be closed out two weeks before PDUFA. Bacterial Contamination Even though Revance Therapeutic...

Revance Therapeutics, Inc. (RVNC) Q2 2022 Earnings Conference Call August 9, 2022 16:30 ET Company Participants Jessica Serra - Head-Investor Relations and ESG Mark Foley - Chief Executive Officer Toby Schilke - Chief Financial Officer Conference Call Parti...

Revance Therapeutics press release ( NASDAQ: RVNC ): Q2 GAAP EPS of -$0.88 beats by $0.03 . Revenue of $28.37M (+50.9% Y/Y) beats by $0.6M . Shares -10.3% . 2022 Financial Outlook Revance expects 2022 GAAP operating expenses to be $375 million to $4...

PDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar lines Reinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar lines Second quarter total revenue of $28...

Conference Call Scheduled for Tuesday, August 9, 2022 at 4:30 p.m. ET. Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter ...

– New data demonstrating the enhancement of membrane binding of the core neurotoxin of BoNT/A by RTP004, Revance’s novel, excipient peptide – – A podium presentation on ASPEN-1: A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, an...

Resubmission of BLA for DAXI for glabellar lines achieved, PDUFA date established for September 8, 2022. The global Botulinum Toxin market is expected to reach $7.71 billion by 2027. Since launch of the RHA Collection, sales reached $100 million, with first-quarter revenue totalin...